Cipla Eyes Respiratory Demand Surge, US Launches by FY27
By Business Desk
Cipla anticipates a surge in respiratory medicine demand, driven by seasonal illnesses and strategic US launches planned for FY27. Strong domestic growth continues.
Cipla anticipates increased demand for its respiratory medicines during the upcoming monsoon and winter seasons, driven by a higher incidence of respiratory infections and allergies. The company maintains a leading position within India’s respiratory pharma market.
- India’s respiratory segment growth: 13% year-over-year as of June 2026
- Foracort brand sales: Surpassed Rs. 1,000 crore
- Q1 FY27 revenue growth: 2.3%
- India business growth: 12.4% year-over-year
- gProventil US market share: 21% of Albuterol MDI market
The company has strategically expanded its product portfolio with recent launches aimed at both domestic and international markets, reinforcing its presence in key therapeutic areas.
Strategic Product Expansion
- Q1 FY27 India launches: Duolin Syncrobreathe (COPD and asthma), Nasowash (nasal congestion), Bilafav M (allergies).
- US market additions: gVentolin launched.
- Sustainability initiative: Developing green-propellant infrastructure for inhalers.
While Q1 FY27 saw modest revenue growth and an EBITDA decline, primarily due to lower US sales of gRevlimid and elevated costs, the India business demonstrated robust performance.
Outlook and Analyst View
- FY27 US launches expected: Four major products, including gAdvair, gGattex, and gSymbicort.
- Anticipated impact: Significant improvement in US sales and margins.
- ICICI Securities rating: BUY.
- ICICI Securities target price: Rs. 1,610.
- Expected recovery: Second half of FY27, driven by new launches gaining traction.
Cipla’s robust domestic market position and a pipeline of significant US launches are set to drive a recovery in the latter half of FY27, as new products begin to contribute to sales.